Výsledky vyhledávání

Akademický článek

Artificial DnaJ Protein for protein production and conformational diseases

Autor: Akinori Hishiya, Keizo Koya

Publikováno v: Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)

Abstract For secreted proteins, proper protein folding is essential not only for biological function but also for secretion itself. Proteins with folding problems are trapped in the endoplasmic reticulum (ER) and are eventually degraded in the cytopl

Externí odkaz: https://doaj.org/article/8bbc8d7634574565816e06db2aa92957

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.

Autor: David A Proia, Kevin P Foley, Tim Korbut, Jim Sang, Don Smith, Richard C Bates, Yuan Liu, Alex F Rosenberg, Dan Zhou, Keizo Koya, James Barsoum, Ronald K Blackman

Publikováno v: PLoS ONE, Vol 6, Iss 4, p e18552 (2011)

There is accumulating evidence that dysregulated JAK signaling occurs in a wide variety of cancer types. In particular, mutations in JAK2 can result in the constitutive activation of STAT transcription factors and lead to oncogenic growth. JAK kinase

Externí odkaz: https://doaj.org/article/5f8979a9202f493f95717a8dd14439d5

Zobrazit plný text záznamu

Data from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

Autor: Keizo Koya, James Barsoum, Yumiko Wada, Luisa Shin Ogawa, Jamie Acquaviva, Shuxia Ye, Jim Sang, Noriaki Tatsuta, Takayo Inoue, Dan Zhou, Ronald K. Blackman, David A. Proia, Kevin P. Foley, Lijun Sun, Zhenjian Du, Weiwen Ying

Targeted inhibition of the molecular chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics. Ganetespib (formerly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae60d0c33c26e54380b34829efd6ddae
https://doi.org/10.1158/1535-7163.c.6536173

Zobrazit plný text záznamu

Supplementary Figure 2 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

PDF file - 98K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::717bc645823d0452677be81b15cc73d4
https://doi.org/10.1158/1535-7163.22499512.v1

Zobrazit plný text záznamu

Supplementary Methods, Figures 1-2 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

PDF file - 126K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0419c2b20bb40ada53d1f5fc54dd6de0
https://doi.org/10.1158/1535-7163.22499509

Zobrazit plný text záznamu

Supplementary Table 2 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

PDF fiel - 59K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7ef0af9192804138843789143796b28
https://doi.org/10.1158/1535-7163.22499503

Zobrazit plný text záznamu

Supplementary Table 1 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

PDF file - 71K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::124e53ac9e88dab5a1bfee6416ca98ed
https://doi.org/10.1158/1535-7163.22499506

Zobrazit plný text záznamu

Supplementary Figure 1 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

PDF file - 280K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0073d34f10ba2d2a7ab3ced86decf1a7
https://doi.org/10.1158/1535-7163.22499515

Zobrazit plný text záznamu

Abstract 429: Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer

Autor: Lei Zhang, Ao Li, Shanzhong Jian, Chengyi Du, Wan Zhu, Yue Tao, Meiwei Wang, Wen Xu, Wenshan Hao, Linda Paradiso, Thomas Myers, Keizo Koya, Jintao Zhang

Publikováno v: Cancer Research. 83:429-429

KRAS is the predominantly mutated RAS isoform, accounting for 85% of RAS mutations in cancers. KRAS G12C mutation occurs in approximately 14% of lung adenocarcinomas and 3% of colorectal adenocarcinomas. Several drugs have been developed that inhibit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ddf7026f0fca326763684e37d8047795
https://doi.org/10.1158/1538-7445.am2023-429

Zobrazit plný text záznamu

Artificial DnaJ Protein for protein production and conformational diseases

Autor: Keizo Koya, Akinori Hishiya

Publikováno v: Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)

For secreted proteins, proper protein folding is essential not only for biological function but also for secretion itself. Proteins with folding problems are trapped in the endoplasmic reticulum (ER) and are eventually degraded in the cytoplasm. In t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69d25dc6cf1fe839cdf9ccca5ae5120b
https://doi.org/10.1038/s41598-017-09067-7

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání